The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so ... gaps in access to medically necessary treatment for patients who are unable to afford the ...

GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes “Today’s data build on the body of evidence supporting depemokimab as an ultra-long-acting treatment and ...

plus another asthma controller and, as add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Also Read: GSK’s ...

A 10% surge in child TB infections in Europe has prompted urgent WHO action, European regulators are evaluating GSK's drug ...

The FDA has accepted GSK’s Biologics License Application for depemokimab as an add-on maintenance treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).

A new asthma treatment, depemokimab ... and 96% did not require hospitalization or emergency department visits. GSK has submitted depemokimab for FDA approval.

According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...

The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD ...